All AbMole products are for research use only, cannot be used for human consumption.
Manidipine dihydrochloride (CV-4093) is a hydrochloride salt of manidipine that is a lipophilic, third-generation, highly vasoselective dihydropyridine calcium antagonist with an IC50 of 2.6 nM. Manidipine dihydrochloride (CV-4093) causes systemic vasodilation by inhibiting the voltage-dependent calcium inward currents in smooth muscle cells. Manidipine dihydrochloride (CV-4093) is used clinically as an antihypertensive. Manidipine dihydrochloride (CV-4093) suppressed the DNA synthesis of vascular smooth muscle cells (VSMC) dose dependently at concentrations of more than 10 nM. Mandipine hydrochloride (1 uM) suppressed proliferation of VSMC to 50% of the control value. Manidipine hydrochloride stimulated the synthesis of GAG at concentrations above 0.01 nM. Manidipine hydrochloride (10 nM) stimulated synthesis of glycosaminoglycans (GAG) to 450% of control.
| Cell Experiment | |
|---|---|
| Cell lines | Mesangial cells |
| Preparation method | Measuring the mitogenic effect by the amout of [3H]thymidine incorporated into DNA of human MCs and by assessment of cell proliferation. In brief, seeding 1 ?105 quiescent cells into a 25-mL cell culture bottle and keeping in low serum medium (0.1% FCS). On the next day, the cells are preincubated for 3 hours with Manidipine (10 nM) followed by stimulation with PDGF-BB (10 ng/mL) or incubated with low serum medium abone. Replacing the medium each day, and counting the cells at days 1, 3 and 5. |
| Concentrations | 10 nM |
| Incubation time | Days 1, 3 and 5 |
| Animal Experiment | |
|---|---|
| Animal models | Normotensive male Wistar-Kyoto rats and male stroke-prone SHR |
| Formulation | Saline |
| Dosages | 1 mg/kg, 3 mg/kg and 10 mg/kg |
| Administration | Administered via p.o. |
| Molecular Weight | 683.62 |
| Formula | C35H38N4O6.2HCl |
| CAS Number | 89226-75-5 |
| Solubility (25°C) | DMSO 20 mg/mL |
| Storage |
Powder -20°C 3 years ; 4°C 2 years In solvent -80°C 6 months ; -20°C 1 month |
[1] Luca Cavalieri, et al. Metabolic effects of manidipine
[2] Paul L McCormack, et al. Delapril/manidipine
[3] Alex Roca-Cusachs, et al. Antihypertensive effect of manidipine
[4] Kate McKeage, et al. Manidipine: a review of its use in the management of hypertension
[5] S M Cheer, et al. Manidipine: a review of its use in hypertension
| Related Calcium Channel Products |
|---|
| CBD3063
CBD3063 is a selective, first-in-class, CRMP2-based peptidomimetic small molecule, which allosterically regulates Cav2.2 to achieve analgesia and pain relief without negative side effect profiles. |
| TTA-A8
TTA-A8 is a short-acting T-type calcium channel antagonist with oral activity, exhibiting an IC50 value of 31.3 nM in the FLIPR depolarization assay. |
| MONIRO-1
MONIRO-1 is a T-type and N-type calcium channel blocker with IC50 values of 34, 3.3, 1.7 and 7.2 µM against hCav2.2, hCav3.1, hCav3.2 and hCav3.3, respectively. |
| Azumolene
Azumolene (EU4093 free base), a Dantrolene analog, is a muscle relaxant. |
| Nexopamil
Nexopamil is a calcium antagonist of Ca2+ channel, 5HT2, 5HT1A, 5HT1C and dopamine D2 receptors. |
All AbMole products are for research use only, cannot be used for human consumption or veterinary use. We do not provide products or services to individuals. Please comply with the intended use and do not use AbMole products for any other purpose.
Products are for research use only. Not for human use. We do not sell to patients.
© Copyright 2010-2024 AbMole BioScience. All Rights Reserved.
